SALTS Act

Bill: 115-hr-6047
Sponsor: full_name: Rep. Thornberry, Mac [R-TX-13]
Introduced: 2018-06-07
Policy area: Crime and Law Enforcement
Subjects: Drug trafficking and controlled substances

Drug, alcohol, tobacco use

Evidence and witnesses

Marketing and advertising
Latest action: action_date: 2018-07-30
text: Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.

Summaries:
action_date: 2018-06-07
action_desc: Introduced in House
text: <p><b>Synthetic Abuse and Labeling of Toxic Substances Act of 2018 or the SALTS Act</b> <p>This bill amends the Controlled Substances Act to set forth factors that may be considered to determine whether a controlled substance analogue is intended for human consumption. (Under current law, a controlled substance analogue that is intended for human consumption is treated as a schedule I controlled substance. A schedule I controlled substance is a drug, substance, or chemical that: has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.)</p>

tv_txt: I 115th CONGRESS 2d Session H. R. 6047 IN THE HOUSE OF REPRESENTATIVES June 7, 2018 Mr. Thornberry introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend the Controlled Substances Act relating to controlled substance analogues.

1. Short title This Act may be cited as the Synthetic Abuse and Labeling of Toxic Substances Act of 2018 or the SALTS Act . 2. Controlled substance analogues Section 203 of the Controlled Substances Act ( 21 U.S.C. 813 ) is amended— (1) by striking A controlled and inserting (a) In general .—A controlled ; and (2) by adding at the end the following: (b) Determination In determining whether a controlled substance analogue was intended for human consumption under subsection (a), the following factors may be considered, along with any other relevant factors: (1) The marketing, advertising, and labeling of the substance. (2) The known efficacy or usefulness of the substance for the marketed, advertised or labeled purpose. (3) The difference between the price at which the substance is sold and the price at which the substance it is purported to be or advertised as is normally sold. (4) The diversion of the substance from legitimate channels and the clandestine importation, manufacture, or distribution of the substance. (5) Whether the defendant knew or should have known the substance was intended to be consumed by injection, inhalation, ingestion, or any other immediate means. (6) Any controlled substance analogue that is manufactured, formulated, sold, distributed, or marketed with the intent to avoid the provisions of existing drug laws. (c) Limitation For purposes of this section, evidence that a substance was not marketed, advertised, or labeled for human consumption, by itself, shall not be sufficient to establish that the substance was not intended for human consumption. .